Wells Fargo analyst Derek Archila upgraded Blueprint Medicines to Equal Weight from Underweight with an unchanged price target of $41.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BPMC:
Wells Fargo analyst Derek Archila upgraded Blueprint Medicines to Equal Weight from Underweight with an unchanged price target of $41.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BPMC: